/C O R R E C T I O N - Pierre Fabre Pharmaceuticals/
In the news release, Pierre Fabre Pharmaceuticals Announces FDA Acceptance of BLA Resubmission for Tabelecleucel for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease, issued 14-Oct-2026 by Pierre Fabre Pharmaceuticals over PR Newswire, we are...
Covered in this story
Call it yourself
No calls on $POST yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Post Holdings →Dalsna Finance is currently tracking 7 stories mentioning Post Holdings, the earliest published 19 May 2026.
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.